Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

And this is demonstrated CRISPR Therapeutics’s first approved therapy, CASGEVY, which treats people suffering from sickle cell disease (SCD) and transfusion-dependent beta-thalassemia.

CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant ...

Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential ...

Indeed, the company has a story to tell. The story’s most exciting chapter involves the use of MaxCyte technology in the production of Casgevy, the first CRISPR-based gene therapy to win FDA ...

Muscat – The Ministry of Health (MoH), represented by the Directorate General of Khoula Hospital, on Sunday launched several health initiatives to be implemented at Khoula and Al-Nahda hospitals over ...

A controversial decision to make plastic wrapping over all checked in luggage mandatory at… You are speaking of a great amount of cash right here amounting so you’re able to hundreds of billions of ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The best free logo maker lets you create eye-catching graphics to market your business completely free. Our team of creatives tested out the best logo makers and the best graphic design software ...

RIYADH: Saudi Arabia has made a medical breakthrough successfully using Casgevy gene (exagamglogene autotemcel) therapy through CRISPR gene editing technology to treat a 13-year-old patient with ...

successfully utilizing Casgevy gene therapy through CRISPR gene editing technology to treat a 13-year-old patient with thalassemia major. The achievement is the first of its kind outside of clinical ...